Resources

Cytotherapy Journal Cover

Cytotherapy

About Cytotherapy

Cytotherapy is the official journal of the International Society for Cell & Gene Therapy. The journal publishes cutting edge findings, clinical trials of cell-based therapies, and news and opinions on all aspects of the rapidly expanding field of cell-based treatments for cancer, degenerative disorders, immunotherapy and stem cell transplantation. The journal focuses especially on the practical translation of scientific developments in the laboratory into clinical practice. Cytotherapy is an essential global resource for clinical researchers, oncologists, hematologists, physicians, and regulatory experts involved in cell and gene processing and therapy.

Top Cited Articles

Powered by Scopus, most cited articles published since 2012:

1. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT)

Journal: Volume 15, Issue 6, June 2013
Authors: Bourin, P.; Bunnell, B.A.; Casteilla, L.; Dominici, M.; Katz, A.J.; March, K.L.; Redl, H.; Rubin, J.P.; Yoshimura, K.; Gimble, J.M.


2. The mesenchymal stromal cells dilemma-does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?

Journal: Volume 15, Issue 1, January 2013
Author: Galipeau, J.


3. Immunological characterization of multipotent mesenchymal stromal cells-The International Society for Cellular Therapy (ISCT) working proposal

Journal: Volume 15, Issue 9, September 2013
Authors: MSC Committee of the International Society for Cellular Therapy (ISCT); Krampera, M.; Galipeau, J.; Shi, Y.; Tarte, K.; Sensebe, L.


4. Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: Production process, content and identification of active components

Journal: Volume 14, Issue 5, May 2012
Authors: Fekete, N.; Gadelorge, M.; Fürst, D.; Maurer, C.; Dausend, J.; Fleury-Cappellesso, S; Mailnder, V.; Lotfi, R.; Ignatius, A.; Sensebe, L.; Bourin, P. ; Schrezenmeier, H.; Rojewski, M.T. 


5. Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing

Journal: Volume 14, Issue 2, February 2012 
Authors: Francois, M.; Copland, I.B.; Yuan, S.; Romieu-Mourez, R.; Waller, E.K.; Galipeau, J.


6. Mesenchymal stromal cell transplantation in amyotrophic lateral sclerosis: A long-term safety study

Journal: Volume 14, Issue 1, January 2012
Author: Mazzini, L.; Kareschi, K.; Ferrero, I.; Miglioretti, M.; Stecco, A.; Servo, S.; Carriero, A.; Monaco, F.; Fagioli, F. 


7. Risk of tumorigenicity in mesenchymal stromal cell-based therapies - Bridging scientific observations and regulatory viewpoints

Journal: Volume 15, Issue 7, July 2013
Authors: Barkholt, L.; Flory, E.; Jekerle, V.; Lucas-Samuel, S.; Ahnert, P.; Bisset, L.; Buscher, D.; Fibbe, W.; Foussat, A.; Kwa, M.; Lantz, O.; Maciulaitis, R.; Palomaki, T.; Schneider, C.K.; Sensebe, L.; Tachdjian, G.; Tarte, K.; Tosca, L.; Salmikangas, P.


8. Phase I trial: The use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia

Journal: Volume 16, Issue 2, February 2014
Authors: Bura, A., Planat-Benard, V.; Bourin, P.; Silvestre, J.S.; Gross, F.; Grolleau, J.L.; Saint-Lebese, B.; Peyrafitte, J.A.; Fleury, S.; Gadelorge, M.; Taurand, M.; Dupuis-Coronas, S.; Leobon, B.; Casteilla, L.


9. Mesenchymal stromal cells and fibroblasts: A case of mistaken identity?

Journal: Volume 14, Issue 5, May 2012
Author: Hematti, P.


10. Is CD34 truly a negative marker for mesenchymal stromal cells?

Journal: Volume 14, Issue 10, November 2012
Authors: Lin, C.S.; Ning, H.; Lin, G.; Lue, T.F.

Journal Leadership

Senior Editor

Donald G. Phinney, PhD

The Scripps Research Institute
United States

Commissioning Editor

Patrick J. Hanley, PhD

Children's National Hospital
United States

Associate Editors

Oscar Lee, MD, PhD
National Yang-Ming University
Taiwan

Luis A. Ortiz, MD
University of Pittsburgh

United States
Anna Pasetto, PhD
Karolinska Institutet

Sweden
Qasim A. Rafiq, PhD
University College London

United Kingdom
Sowmya Viswanathan, PhD
University Health Network

Canada

About the Journal

The journal's scope includes research in:

  • Stem cell processing and transplantation
  • Cell-based therapies of malignant and non-malignant blood diseases
  • CancerStem cell plasticity
  • Autoimmune diseases
  • Immunotherapy
  • Congenital disorders
  • Novel molecular therapies
  • Gene therapy
  • Microvesicle biology and therapeutic application

Readership and Target Group: Cytotherapy provides essential reading for scientists, physicians, technicians and regulatory experts involved in cell processing and therapy. It is a vital resource for hematologists, oncologists, and immunologists and the growing number of physicians from many disciplines involved in tissue repair and stem cell research, cytokine investigators, cancer biologists and biotherapists.

Keywords: Cytotherapy, Cytokine, Translational Research, Stem Cells, Cellular Therapies, Vaccines, Gene Therapy, Immunotherapy, Tissue Engineering, Blood and Bone Marrow, T cells.

Submit a Manuscript

Cytotherapy publishes original papers, reviews, novel hypotheses, short communications, book reviews and editorials. Submitted manuscripts will be reviewed by at least two reviewers. Authors will be notified within 30 working days of receipt, whether the manuscript is accepted, requires revision, or is rejected. All manuscripts will be published within 5 months from the date of acceptance.

Submit Now